Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Multi-region sampling with paired sample sequencing analyses reveals sub-groups of patients with novel patient-specific dysregulation in Hepatocellular Carcinoma

Fig. 1

Per-patient analysis identified patient specific dysregulated genes. A: Data acquisition overview for multi-region RNA-seq data and clinical data of patients. B: Comparison between all-patients and per-patient DE analyses. C: Number of up-/down-regulated genes above a given DEPC threshold against different DEPC thresholds. DEPC cutoff for up-/down-regulated genes was determined based on two standard deviations. D: Visualization of the proportion of AP vs NAP genes in up-/down-regulated genes above the respective DEPC thresholds. E: Standard deviations of normal gene expression of AP genes against NAP genes. F: Overlayed density plots of tumour and normal gene expression of the top 50 AP/NAP genes with highest DEPC counts. G: Normalized gene expression and their respective log2FoldChange values from per-patient analysis of example genes (CDK1, CD24 & WNT5A). Only CDK1 was also found to be up-regulated in all-patients analysis. H: GSEA results for the 328 up-regulated NAP genes against the REACTOME (left) and CGP gene sets (right) from MSigDB. Top 10 enriched gene sets were shown

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us